NCT02253251 Clinical Validation of the Role of microRNA Binding Site Mutations in Cancer Risk, Prevention and Treatment
| NCT ID | NCT02253251 |
| Status | Recruiting |
| Phase | — |
| Sponsor | MiraKind |
| Condition | Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 15,000 participants |
| Start Date | 2014-09 |
| Primary Completion | 2030-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 15,000 participants in total. It began in 2014-09 with a primary completion date of 2030-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The investigators will recruit and enroll individuals that may have the KRAS-variant or other microRNA binding site mutations to join registry studies. The investigators will allow individuals to obtain their results through a physician at the completion of the studies. The investigators current focus is cancer and autoimmunity.
Eligibility Criteria
Inclusion Criteria: * Personal or family history of cancer * Personal history of endometriosis, or autoimmunity Exclusion Criteria: * Younger than 18 * Non-english speaking and unable to understand and sign the consent
Contact & Investigator
Joanne Weidhaas, MDPhD
PRINCIPAL INVESTIGATOR
MiraKind
Frequently Asked Questions
Who can join the NCT02253251 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT02253251 currently recruiting?
Yes, NCT02253251 is actively recruiting participants. Contact the research team at joanne@mirakind.org for enrollment information.
Where is the NCT02253251 trial being conducted?
This trial is being conducted at Los Angeles, United States.
Who is sponsoring the NCT02253251 clinical trial?
NCT02253251 is sponsored by MiraKind. The principal investigator is Joanne Weidhaas, MDPhD at MiraKind. The trial plans to enroll 15,000 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.